% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fresnais:167771,
      author       = {M. Fresnais and E. Yildirim and S. Karabulut and D. Jäger
                      and I. Zörnig and J. Benzel$^*$ and K. W. Pajtler$^*$ and
                      S. M. Pfister$^*$ and J. Burhenne and W. E. Haefeli and R.
                      Longuespée},
      title        = {{R}apid {MALDI}-{MS} {A}ssays for {D}rug {Q}uantification
                      in {B}iological {M}atrices: {L}essons {L}earned, {N}ew
                      {D}evelopments, and {F}uture {P}erspectives.},
      journal      = {Molecules},
      volume       = {26},
      number       = {5},
      issn         = {1420-3049},
      address      = {Basel},
      publisher    = {MDPI44576},
      reportid     = {DKFZ-2021-00535},
      pages        = {1281},
      year         = {2021},
      note         = {2021 Feb 26;26(5):1281},
      abstract     = {Matrix-assisted laser desorption/ionization mass
                      spectrometry (MALDI-MS) has rarely been used in the field of
                      therapeutic drug monitoring, partly because of the
                      complexity of the ionization processes between the compounds
                      to be quantified and the many MALDI matrices available. The
                      development of a viable MALDI-MS method that meets
                      regulatory guidelines for bioanalytical method validation
                      requires prior knowledge of the suitability of (i) the MALDI
                      matrix with the analyte class and properties for ionization,
                      (ii) the crystallization properties of the MALDI matrix with
                      automation features, and (iii) the MS instrumentation used
                      to achieve sensitive and specific measurements in order to
                      determine low pharmacological drug concentrations in
                      biological matrices. In the present hybrid article/white
                      paper, we review the developments required for the
                      establishment of MALDI-MS assays for the quantification of
                      drugs in tissues and plasma, illustrated with concrete
                      results for the different steps. We summarize the necessary
                      parameters that need to be controlled for the successful
                      development of fully validated MALDI-MS methods according to
                      regulatory authorities, as well as currently unsolved
                      problems and promising ways to address them. Finally, we
                      propose an expert opinion on future perspectives and needs
                      in order to establish MALDI-MS as a universal method for
                      therapeutic drug monitoring.},
      keywords     = {MALDI (Other) / mass spectrometry (Other) / targeted
                      quantification (Other) / therapeutic drug monitoring
                      (Other)},
      cin          = {B062 / HD01},
      ddc          = {540},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33652935},
      doi          = {10.3390/molecules26051281},
      url          = {https://inrepo02.dkfz.de/record/167771},
}